CircRNA_0044556 affects the sensitivity of triple-negative breast cancer cells to paclitaxel by regulating miR-665

Jing-jing Chen Peng Shi Zhi-chao Cui Nan Jiang Jie Ma a Department of Breast Surgery (No.1),Tangshan People's Hospital,Tangshan,Chinab Department of Urology,Tangshan People's Hospital,Tangshan,China
DOI: https://doi.org/10.1080/1120009x.2024.2345028
2024-06-09
Journal of Chemotherapy
Abstract:CircRNAs have been implicated in the development of resistance in triple-negative breast cancer (TNBC). However, the association between circRNA_0044556 and paclitaxel (PTX) resistance in TNBC is still limited. Therefore, the purpose of this study was to investigate the effect of circRNA_0044556 on biological function and PTX resistance in TNBC cells. PTX-resistant TNBC cells (MDA-MB-231/PTX) were obtained by continuously exposing MDA-MB-231 cells to increasing paclitaxel levels. The expression levels of circRNA_0044556 and miR-665 were measured by qRT–PCR. The regulatory relationship between miR-665 and circRNA_0044556 was verified by biological information website analysis and double-luciferase reporter gene detection experiments. MTT assay, clone assay, flow cytometry and Western blot analysis were used to evaluate the influence of cell biological function. Elevated circRNA_0044556 was observed in TNBC, and paclitaxel increased the expression of circRNA_0044556 in TNBC cells. In TNBC, circRNA_0044556 acted as a ceRNA for miR-665. In addition, low expression of circRNA_0044556 combined with miR-665 inhibited the proliferation of TNBC cells and paclitaxel-resistant TNBC cells while inducing cell death. Our study demonstrated that the downregulation of circRNA_0044556 inhibits the malignant progression of TNBC cells and paclitaxel resistance via miR-665. Thus, circRNA_0044556 may be a potential therapeutic target for PTX-resistance TNBC.
oncology,pharmacology & pharmacy,infectious diseases
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the role and mechanism of circular RNA (circRNA_0044556) in the resistance of triple - negative breast cancer (TNBC) cells to paclitaxel (PTX). Specifically, the researchers hope to understand whether circRNA_0044556 affects the biological functions of TNBC cells and their sensitivity to paclitaxel by regulating the expression of miR - 665. This includes evaluating the relationship between the expression level of circRNA_0044556 and miR - 665, and how this relationship affects the proliferation, apoptosis and resistance ability of TNBC cells to paclitaxel. The research background indicates that although paclitaxel is an effective chemotherapeutic drug for treating advanced triple - negative breast cancer, patients often develop acquired resistance after being initially effective during treatment, resulting in no significant improvement in long - term survival rates. Therefore, exploring the molecular mechanisms related to paclitaxel resistance is crucial for improving the overall response rate and survival rate of TNBC patients. This paper experimentally verified that circRNA_0044556 is up - regulated in TNBC cells, and its expression level increases with paclitaxel treatment. Further, through loss - of - function experiments, it was found that down - regulating circRNA_0044556 can inhibit the malignant phenotype of TNBC cells and paclitaxel resistance, and these effects are partly achieved by sponging miR - 665. This provides a new perspective for understanding the molecular mechanisms of TNBC and may provide a new target for the clinical treatment of TNBC with paclitaxel resistance.